FDA Approves First Gene Therapy for Genetic Hearing Loss as Regeneron Strikes Pricing Deal
The FDA approved Regeneron's Otarmeni, the first gene therapy for genetic hearing loss, as the company agreed to a drug pricing deal with the Trump administration.











